Siemens Medical Solutions USA, Inc.

Westfaelische Wilhelms-Universitaet Muenster

Westfaelische Wihelms-Universitaet Muenster

Michael Schaefers

Andreas Faust

Sven Hermann

Guenter Haufe

Wei Zhang

Joseph C Walsh

Gang Chen

Umesh B Gangadharmath

Dhanalakshmi Kasi

Anna Katrin Szardenings

Eric Wang

Anjana Sinha

Chul Yu

Changhui Liu

Johannes Roth

Thomas Vogl

Petra Keul

Harmuth C Kolb

Klaus Kopka

Verena Hugenberg

Stefan Wagner

Hans-Joerg Breyholz

Bodo Levkau

Stefani Silke Schilson

The present application provides quinoline-3-carboxamide compounds covalently linked to a label for use in the diagnosis of an inflammatory disease at local site. The above mentioned compounds can be used to detect or image accumulation of S100A9 in the body of a subject at sites of inflammation, using in vivo non-invasive molecular imaging techniques for the detection of said compounds. Accordingly, labeled quinoline-3-carboxamide compounds can be applied to evaluate the risk of a subject of developing an inflammatory disease and to follow the progress of the disease.

Quinoline-3-carboxamide compounds and their use in diagnosis

The present invention relates to novel compounds of formulae (I) and (II) which are useful in the prevention, treatment and diagnosis, in vivo diagnosis of diseases or disorders related to S1P receptors, in particular, in diseases which are connected to the regulatory function of sphingosine-1-phosphate (S1P) and its analogs, such as inflammation, pain, autoimmune diseases and cardiovascular diseases.

Ligands for targeting of S1P receptors for in vivo imaging and treatment of diseases

Novel compounds and pharmaceutical compositions having MMP inhibitory activity are disclosed, which have been found to be particularly useful in the prevention, treatment and diagnostic imaging of diseases associated with an unpaired activity of MMP, amongst others MMP-2, MMP-8, MMP-9 and/or MMP-13 to name a few. The compounds of the present invention are useful for the prevention, the treatment and the in vivo diagnostic imaging of a range of disease states (inflammatory, malignant and degenerative diseases) where specific matrix metalloproteinases are known to be involved.

Compounds with matrix-metalloproteinase inhibitory activity and imaging agents thereof

Growing community of inventors

Havixbeck, Germany

Michael Schaefers